Last reviewed · How we verify
NCT05377047: TAORMINA
Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer
NA trial testing SABR in Breast Cancer Stage IV in 345 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Vastra Gotaland Region |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 345 |
| Start date | 19 September 2022 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across Sweden |
Drugs / interventions tested
- SABR
Conditions studied
- Breast Cancer Stage IV — all drugs for Breast Cancer Stage IV →
- Oligometastatic Disease — all drugs for Oligometastatic Disease →
Sponsor
Vastra Gotaland Region — full company profile →
Who can join
18 and older, any sex, with Breast Cancer Stage IV or Oligometastatic Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy (investigational arm) versus systemic therapy alone (control arm) as 1st line therapy.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
A critical review on oligometastatic disease: a radiation oncologist's perspective.
Pacifico P, Colciago RR, De Felice F, Boldrini L, et al · · 2022 · cited 12× · PMID 36071292 · DOI 10.1007/s12032-022-01788-8 -
Navigating Breast Cancer Oligometastasis and Oligoprogression: Current Landscape and Future Directions.
Yoon SM, Bazan JG. · · 2024 · cited 10× · PMID 38652425 · DOI 10.1007/s11912-024-01529-2 -
The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial.
Ruicci KM, Helou J, Barry A, Ye XY, et al · · 2026 · PMID 42011409 · DOI 10.1016/j.ctro.2026.101164 -
Management of Musculoskeletal Oligometastatic Disease in Breast Cancer.
Kon-Liao K, Layme J, Otero López-Lavalle A, Gonzalez MR, et al · · 2025 · PMID 41228369 · DOI 10.3390/cancers17213578 -
Impact of stereotactic body radiation therapy on systemic therapeutic line change in oligometastatic breast cancer.
Leblanc J, de Nonneville A, Nicolas C, Gonçalves A, et al · · 2025 · PMID 40737892 · DOI 10.1016/j.breast.2025.104546
Verify or expand the search:
- PubMed search for NCT05377047
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of SABR
Trials testing the same drug.
- NCT06937281 — SABR PRIMER - Evaluating Stereotactic Ablative Radiotherapy for Primary and Regional Breast Tumors · NA · not yet recruiting
- NCT06521866 — Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorec · Phase 2 · recruiting
- NCT05311527 — UroLift System With SAbR for Prostate Cancer and BPH · NA · completed
- NCT06613295 — Separation Surgery Followed by Stereotactic Ablative Body Radiotherapy (SABR) Versus SABR Alone for Spinal Metastases · NA · recruiting
- NCT04742972 — Prostate PMSABR Study · NA · withdrawn
Other recruiting trials for Breast Cancer Stage IV
Currently open trials in the same condition.
- NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
- NCT07371585 — Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management · Phase 2 · recruiting
- NCT06830382 — HER2-PET as a Precision Imaging Tool for Treatment With HER2-ADC in HER2-expressing mBC · recruiting
- NCT06889688 — Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast · Phase 3 · active not recruiting
- NCT06678269 — A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer · Phase 1 · recruiting
Other Vastra Gotaland Region trials
Trials by the same sponsor.
- NCT07430865 — The RECOVER Study - Postpartum Recovery of Pelvic Floor Structures and the Impact of Early Rehabilitation · NA · recruiting
- NCT07472335 — Home-based Acute Care for Older Persons Initiated by the Emergency Medical and Ambulance Services - a Retrospective Obse · not yet recruiting
- NCT07246577 — The VGR GCA Cohort: Ultrasound, Biopsy and Biomarkers - Novel Methods for Diagnosis, Monitoring and Prognosis in Giant C · recruiting
- NCT07449338 — Prospective Cohort Study of Response and Tolerability of Accelerated Intermittent Theta-burst Stimulation (1W-AiTBS) · not yet recruiting
- NCT07334340 — Modified vs Standard CDED: Evaluation of a Nordic Adaptation of Nutritional Therapy in Paediatric Crohn's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05377047 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Vastra Gotaland Region
- Last refreshed: 21 October 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05377047.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing